A forthcoming federal hearing on cannabis policy is facing criticism after the DEA approved participation exclusively from individuals and organizations that have voiced skepticism about marijuana legalization, leaving reform advocates and industry representatives out of the discussion.
The hearing, set for June 29 in Virginia, will focus on issues tied to the federal classification of marijuana. The proceedings could influence future decisions affecting cannabis businesses, taxation rules, banking access, and broader regulatory policy across the country.
Documents released by the DEA show that seven participants were selected to take part. Each of those approved has previously expressed concerns about legalization or the expansion of cannabis access. Groups representing consumers, patients, licensed marijuana operators, and legalization supporters were not granted a seat at the hearing.
The development has attracted attention in Michigan, where the legal cannabis market has become a major economic force. Marijuana sales in the state surpassed $3 billion last year, placing Michigan among the largest regulated cannabis markets in the nation.
Those approved to participate include Smart Approaches to Marijuana, the National Drug and Alcohol Screening Association, DUID Victim Voices, representatives from Nebraska, Louisiana, Idaho, and Indiana, the Tennessee Bureau of Investigation, along with pharmacist Dr. Phillip Drum and physician Dr. Kenneth Finn.
Critics point out that every participant selected has publicly raised concerns about legalization or expanded cannabis availability. Meanwhile, organizations that support reform were denied participation. Among them was the National Organization for the Reform of Marijuana Laws.
Following the decision, Paul Armentano, NORML’s Deputy Director, argued that cannabis users deserve representation in a process that could help determine the plant’s future legal status under federal law. He noted that millions of U.S. citizens use marijuana responsibly and should have an opportunity to be heard.
The DEA rejected requests from several reform groups after concluding they would not be negatively affected by moving marijuana to Schedule 3.
Although certain medical marijuana products and approved cannabis-based medications were moved to Schedule 3 earlier this year, major policy questions remain unresolved. Issues involving recreational cannabis, federal tax treatment, banking services, and long-term regulation continue to be debated.
The hearing is not expected to result in immediate policy amendments. Instead, it will contribute to an administrative record that may shape future federal action. As testimony begins and extends into July, many within the cannabis sector will be watching closely to determine whether the process is viewed as fair, balanced, and credible.
Businesses like Innovative Industrial Properties Inc. (NYSE: IIPR) that serve companies in the marijuana ecosystem will be hoping that the rescheduling hearing collects actionable views that accurately capture the realities on the ground.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN